var data={"title":"Cyproterone (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cyproterone (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5963?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cyproterone-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cyproterone (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155793\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Androcur;</li>\n      <li>Androcur  Depot;</li>\n      <li>Med-Cyproterone;</li>\n      <li>Riva-Cyproterone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155804\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiandrogen;</li>\n      <li>\n        Antineoplastic Agent, Antiandrogen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155794\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced (palliative treatment):</b> Males:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 200 to 300 mg daily in 2 to 3 divided doses (maximum: 300 mg daily); following orchiectomy, reduce dose to 100 to 200 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 300 mg (3 mL) once weekly; reduce dose in orchiectomized patients to 300 mg (3 mL) every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> May interchange between oral and IM administration during chronic therapy; dosages should remain within usual ranges (oral: 100 to 300 mg daily; IM: 300 mg weekly or every 2 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Treatment of paraphilia/hypersexuality (off-label use) (Guay 2009; Reilly 2000): </b> Males (<b>Note:</b> Avoid use if active pituitary pathology, hepatic failure, or thromboembolic disease): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral: 50 to 600 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: 300 to 600 mg weekly or every other week</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062977\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155795\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); use with caution</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155796\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated with hepatic impairment or liver disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10241394\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution, as acetate: 100 mg/mL (3 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Androcur Depot: 100 mg/mL (3 mL) [contains benzyl benzoate and castor oil]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, as acetate: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Androcur: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11218428\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155778\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM: Administer IM injections slowly and avoid intravascular injection which can lead to pulmonary microembolism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Administer tablets at the same time each day, after meals and with liquids. Tablets may be divided into equal halves.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130958\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (meets NIOSH 2016 criteria). This medication is not on the NIOSH (2016) list; however, it meets the criteria for a hazardous drug. Drugs are classified as hazardous based on their properties; the properties of a hazardous drug include one or more of the following characteristics: carcinogenic, teratogenic (or other developmental toxicity), reproductive toxicity, organotoxic at low doses, genotoxic, and/or new agents with structural or toxicity profiles similar to existing hazardous agents. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. For IM preparation, NIOSH recommends double gloving, a protective gown, and preparation in a controlled device or the use of ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator); if not prepared in a controlled device, respiratory and eye/face protection are recommended. Double gloving and a protective gown are recommended during IM administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155777\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer:</b> Palliative treatment of advanced prostate cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722049\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Paraphilia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26116832\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">\n          <b>ALERT: Canadian Boxed Warning:</b> Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155769\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac failure, cerebrovascular accident, edema, hypotension, myocardial infarction, phlebitis, pulmonary embolism (including oil microembolism), shock, syncope, tachycardia, thrombosis (deep vein thrombosis, embolism, superficial venous thrombosis), vasodepressor syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Abnormal gait, aphasia, brain disease, chills, coma, depression, dizziness, fatigue, headache, hemiplegia, lassitude, malaise, myasthenia, personality disorder, psychotic depression, restlessness, vascular headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, eczema, erythema nodosum, exfoliative dermatitis, loss of body hair (patchy), maculopapular rash, pruritus, skin discoloration, skin photosensitivity, skin rash, urticaria, xeroderma (sebum reduction)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Adrenal suppression (dose-related), decreased libido, diabetes mellitus, galactorrhea, gynecomastia, hirsutism, hot flash, hypercalcemia, hyperglycemia, hypernatremia, negative nitrogen balance, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Anorexia, constipation, diarrhea, dyspepsia, glossitis, nausea, pancreatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Benign breast nodule, crystalluria, hematuria, impotence, inhibition of spermatogenesis, urinary frequency, uterine hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, bladder carcinoma, decreased prothrombin time, hemolytic anemia, hemorrhage, hepatic carcinoma, hypochromic anemia, increased serum fibrinogen, leukocytosis, leukopenia, meningioma (with chronic therapy), normocytic anemia, thrombocytopenia, uterine fibroid enlargement</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Ascites, cholestatic jaundice, hepatic cirrhosis, hepatic coma, hepatic failure, hepatic insufficiency (dose-related), hepatic necrosis, hepatic neoplasm, hepatitis, hepatomegaly, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular and skeletal: Osteoporosis, scleroderma, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Accommodation disturbance, blindness, optic atrophy, optic neuritis, retinal thrombosis, retinal vascular disease, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Asthma, cough, dyspnea, hyperventilation, pulmonary fibrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155781\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cyproterone or any component of the formulation; liver disease or hepatic dysfunction; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumors (if not due to metastases from prostate cancer); presence or history of meningioma; wasting diseases (except inoperable prostate cancer); severe chronic depression; existing thromboembolic processes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155767\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Adrenalcortical function suppression:  Has been reported with use; monitor adrenal function periodically during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anemia: Hypochromic anemia has been observed (rarely); monitor CBC regularly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antiandrogen withdrawal syndrome: Antiandrogens may promote prostate cancer growth in some patients with metastatic prostate cancer; discontinue therapy immediately with increasing prostate specific antigen (PSA) levels and monitor 6 to 8 weeks for withdrawal response prior to initiating alternative treatment. Decreased PSA levels and/or clinical improvement have been reported following therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carcinogenesis: Benign and malignant hepatic tumors have been observed (rarely) after use; rule out the presence of tumor in patients presenting with severe upper abdominal discomfort, hepatic enlargement or signs of intra-abdominal hemorrhage. Meningioma formation has been reported with chronic therapy (years) at doses &ge;25 mg/day. Initiation of therapy in patients with a history or presence of meningioma is contraindicated; discontinue treatment in patients diagnosed with meningioma. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: Lassitude, weakness, and fatigue are common during first few weeks of treatment; symptoms usually lessen ~about 3 months after therapy initiation. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Dermatologic effects: Dry skin and/or transient alopecia may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gynecomastia: Hyperplasia of the breast has been reported; subsides usually within 1 to 3 months after therapy discontinuation and/or dose reduction. Risk of treatment failure should be considered prior to discontinuation or dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity:<b> [Canadian Boxed Warning]: Use of cyproterone is associated with dose-dependent hepatotoxicity (jaundice, hepatitis, acute hepatic failure) including fatal case reports with doses &ge;100 mg/day.</b> Most reported fatalities were in males treated for prostate cancer. Hepatotoxicity typically develops a few weeks to several months after treatment initiation. Assess hepatic function prior to treatment initiation and regularly thereafter particularly if signs/symptoms of hepatotoxicity occur; discontinue in patients with evidence of hepatic injury. Use in patients with prior or existing hepatic disease is contraindicated. Use caution with concurrent use of other hepatotoxic drugs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Metabolic effects: Changes in lipid profile, hypercalcemia, and/or fluid retention may occur; a negative nitrogen balance is usual at therapy initiation but typically corrects itself within 3 months of ongoing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Respiratory effects: Shortness of breath was commonly observed in patients receiving doses of 300 mg/day; use caution in patients with existing pulmonary dysfunction (may be more susceptible to effects).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thromboembolism: May increase the risk of thromboembolism (particularly when used in combination with ethinyl estradiol); discontinue use immediately with signs/symptoms of thrombophlebitis or thromboembolism. Use with caution in patients with an inoperable prostate tumor, history of thromboembolic processes, sickle cell anemia or severe diabetes with vascular changes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in cardiovascular disease; may cause fluid retention</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Depression: Use with caution in patients with a history of depression (contraindicated in severe chronic depression); has been associated with an increased incidence of depression, particularly early in the course of therapy (initial 6t o 8 weeks).  Monitor closely in patients with tendency toward depressive episodes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes or impaired glucose tolerance, may cause alterations in glucose metabolism. Monitor for loss of glucose control; may require adjustments in diabetes medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Injection: Solution is oil based and must be injected by slow intramuscular injection only; avoid intravascular injection. Pulmonary microembolism of oily solutions can occur and lead to cough, dyspnea, angina and vasovagal reactions (eg, syncope, malaise, dizziness, hyperhidrosis, paresthesia). Reactions can occur during or immediately after the injection and are reversible; may usually be managed with supportive care (eg, oxygen).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ethanol consumption: Although the relevance to the treatment of prostate cancer is unknown, the antiandrogen effects in hypersexuality may be reduced with ethanol. Ethanol should be avoided during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Combination therapy: Retrospective meta-analysis data suggest that 5-year survival rates may be lower when used concomitantly with a GnRH agonist or orchiectomy versus patients treated with castration alone. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[Canadian Boxed Warning]:</b> Should be prescribed and managed by a clinician experienced with hormonal therapy in prostate cancer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299112\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak); <b>Induces</b> CYP2E1 (weak/moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6219608\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9295&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May diminish the therapeutic effect of Cyproterone. More specifically, alcohol may interfere with antiandrogenic effects of Cyproterone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Progestins may diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.  Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">C1 inhibitors: Progestins may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Antiandrogens may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP1A2 Substrates (High risk with Inducers): Cyproterone may decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2E1 Substrates (High risk with Inducers): Cyproterone may decrease the serum concentration of CYP2E1 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Cyproterone may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).  Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.<b> Exceptions: </b>Pitavastatin; Pravastatin; Rosuvastatin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Antiandrogens may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Progestins may enhance the thrombogenic effect of Pomalidomide.  Management: Canadian pomalidomide labeling recommends caution with use of hormone replacement therapy and states that hormonal contraceptives are not recommended. US pomalidomide labeling does not contain these specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins.  Management: Ulipristal for uterine fibroids (Canadian indication): avoid progestins within 12 days of stopping ulipristal; as emergency contraceptive (U.S. indication): avoid progestins within 5 days of stopping ulipristal.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155790\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Ethanol may reduce the effect of cyproterone (not established in the treatment of prostatic carcinoma). Management: Avoid concurrent use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155782\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Not indicated for use in women. In males, sperm count and volume of ejaculate will be reduced at oral doses of 50 to 300 mg/day. After ~2 months of treatment, infertility may be noted. Changes are reversible upon discontinuation of therapy, usually within 3 to 5 months although in some patients may take up to 20 months.  Production of abnormal spermatozoa has been observed although the effect on fertilization or embryo formation is unknown. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099229\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Not indicated for use in women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9480488\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Tablets should be taken after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155773\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests should be performed at baseline and periodically thereafter, or with signs or symptoms suggestive of hepatotoxicity. CBC, adrenal function, electrolytes, fasting blood glucose and glucose tolerance (diabetic patients) should be monitored periodically. In patients with PSA progression, monitor for withdrawal response syndrome (eg, decrease in PSA levels) for 6 to 8 weeks following therapy discontinuation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Treatment of paraphilia/hypersexuality (Guay 2009; Reilly, 2000): ECG; hepatic function test (baseline and during treatment if suspected hepatotoxicity); CBC (baseline); serum testosterone (baseline then monthly for 4 months then every 6 months); serum luteinizing hormone and prolactin (baseline and every 6 months); follicle-stimulating hormone (baseline); glucose; bone scan (baseline then annually) if serum testosterone significantly suppressed; blood pressure; weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155766\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Cyproterone is a steroid with antiandrogenic, antigonadotropic, and progestin-like activity. Blocks binding of dihydrotestosterone (DHT) to prostatic cancer cells and exerts negative feedback on hypothalamic-pituitary axis by inhibiting luteinizing hormone (LH) secretion leading to decreased testosterone production.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155780\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Complete </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 96% (Guay 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; primary metabolite is 15beta-hydroxy-cyproterone acetate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IM: 20.6 L/kg (Guay 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 88% (Guay 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Oral: 38 &plusmn; 5 hours; Depot injection: 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Oral: 3 to 4 hours; Depot injection: 3.4 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (60%); urine (33%; mainly as unconjugated metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F155783\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Androcur (AE, AR, AT, AU, BE, BG, BH, BR, CH, CN, CO, CY, CZ, DE, DK, DO, EE, EG, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IL, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NL, PE, PK, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, TW, UY, VE, VN, ZA);</li>\n      <li>Androcur Dep (QA);</li>\n      <li>Androkur (UA);</li>\n      <li>Androstat (EC, PY);</li>\n      <li>Armocur (IL);</li>\n      <li>Ciproplex (PY);</li>\n      <li>Ciproterona (CL);</li>\n      <li>Cyprohexal (AU);</li>\n      <li>Cypron 50 (IL, MY);</li>\n      <li>Cyprone (AU);</li>\n      <li>Cyproplex (BE, TW);</li>\n      <li>Cyprostat (AU, GB);</li>\n      <li>Cyrona (TW);</li>\n      <li>Kaliale (FR);</li>\n      <li>Procur (AU, NZ, SG);</li>\n      <li>Prostaden (UY);</li>\n      <li>Siterone (NZ);</li>\n      <li>Virilit (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Androcur (cyproterone) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; February 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21504253\"></a>Garcia FD, Thibaut F. Current concepts in the pharmacotherapy of paraphilias. <i>Drugs</i>. 2011;71(6):771-790.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/21504253/pubmed\" target=\"_blank\" id=\"21504253\">21504253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19243704\"></a>Guay DR, &ldquo;Drug Treatment of Paraphilic and Nonparaphilic Sexual Disorders,&rdquo; <i>Clin Ther</i>, 2009, 31(1):1-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/19243704/pubmed\" target=\"_blank\" id=\"19243704\">19243704</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lukka H, Waldron T, Klotz L, et al, &quot;Maximal Androgen Blockade for the Treatment of Metastatic Prostate Cancer-- A Systematic Review,&quot; <i>Curr Oncol</i>, 2006, 13(3):81-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/17576447/pubmed\" target=\"_blank\" id=\"17576447\">17576447</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10986575\"></a>Reilly DR, Delva NJ, and Hudson RW, &ldquo;Protocols for the Use of Cyproterone, Medroxyprogesterone, and Leuprolide in the Treatment of Paraphilia,&rdquo; <i>Can J Psychiatry</i>, 2000, 45(6):559-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/10986575/pubmed\" target=\"_blank\" id=\"10986575\">10986575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schroder FH, &quot;Cyproterone Acetate--Mechanism of Action and Clinical Effectiveness in Prostate Cancer Treatment,&quot; <i>Cancer</i>, 1993, 72(12 Suppl):3810-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/8252496/pubmed\" target=\"_blank\" id=\"8252496\">8252496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thibaut F, De La Barra F, Gordon H, et al, &ldquo;The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Paraphilias,&rdquo; <i>World J Biol Psychiatry</i>, 2010, 11(4):604-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyproterone-united-states-not-available-drug-information/abstract-text/20459370/pubmed\" target=\"_blank\" id=\"20459370\">20459370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9295 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F155793\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F155804\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F155794\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062977\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F155795\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F155796\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10241394\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11218428\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F155778\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130958\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F155777\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722049\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F26116832\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F155769\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F155781\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F155767\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299112\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6219608\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F155790\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F155782\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21099229\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F9480488\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F155773\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F155766\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F155780\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F155783\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9295|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cyproterone-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Cyproterone (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}